A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed an adjunctive antiepileptic drug. The patients were followed up over a 6-month period. The interview included questions on Quality of Life, side-effects, adverse events and seizure frequency and severity. We operationally defined patients ‘satisfaction’ as (i) still on new drug; (ii) experiencing no side-effects (iii) experiencing no adverse events and (iv) had a greater than 50% reduction in seizures. A total of 13 patients (17%) reported being ‘satisfied’ according to our operational definition
AbstractIntroductionPregabalin (PGB) was licensed in the EU in 2004 as an adjunctive therapy in part...
SummaryObjectiveRetention rates of five new anti-epileptic medications (AEDs) were compared in order...
OBJECTIVE: To evaluate the value of alternative monotherapy versus adjunctive therapy in partial epi...
A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed...
SummaryIntroduction:The tolerability of lamotrigine as adjunctive and monotherapy in patients requir...
AbstractThe objective of this study was to compare the relative cost-effectiveness of two AEDs by a ...
AbstractIn order to select a new medication for a patient with epilepsy, it would be helpful to have...
AbstractObjectivesThe present study evaluated patterns of the use of antiepileptic drugs (AEDs) and ...
This open, clinical study describes the use of lamotrigine in 200 adults and children with drug resi...
AbstractClinical trials of new antiepileptic drugs (AEDs) include regulatory studies aimed at demons...
SummaryPurpose:Lamotrigine (LTG), vigabatrin (VGB) and gabapentin (GBP) are three anti-epileptic dru...
AbstractThe study examined changes in the use of antiepileptic drugs (AEDs) in a large hospital for ...
The objective of this study was to compare the efficacy and tolerability of two new antiepileptic dr...
A number of clinical trials that test the efficacy and safety of the newer antiepileptic drugs (AEDs...
Despite the recent entry into the market-place of a range of new pharmacological treatments for epil...
AbstractIntroductionPregabalin (PGB) was licensed in the EU in 2004 as an adjunctive therapy in part...
SummaryObjectiveRetention rates of five new anti-epileptic medications (AEDs) were compared in order...
OBJECTIVE: To evaluate the value of alternative monotherapy versus adjunctive therapy in partial epi...
A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed...
SummaryIntroduction:The tolerability of lamotrigine as adjunctive and monotherapy in patients requir...
AbstractThe objective of this study was to compare the relative cost-effectiveness of two AEDs by a ...
AbstractIn order to select a new medication for a patient with epilepsy, it would be helpful to have...
AbstractObjectivesThe present study evaluated patterns of the use of antiepileptic drugs (AEDs) and ...
This open, clinical study describes the use of lamotrigine in 200 adults and children with drug resi...
AbstractClinical trials of new antiepileptic drugs (AEDs) include regulatory studies aimed at demons...
SummaryPurpose:Lamotrigine (LTG), vigabatrin (VGB) and gabapentin (GBP) are three anti-epileptic dru...
AbstractThe study examined changes in the use of antiepileptic drugs (AEDs) in a large hospital for ...
The objective of this study was to compare the efficacy and tolerability of two new antiepileptic dr...
A number of clinical trials that test the efficacy and safety of the newer antiepileptic drugs (AEDs...
Despite the recent entry into the market-place of a range of new pharmacological treatments for epil...
AbstractIntroductionPregabalin (PGB) was licensed in the EU in 2004 as an adjunctive therapy in part...
SummaryObjectiveRetention rates of five new anti-epileptic medications (AEDs) were compared in order...
OBJECTIVE: To evaluate the value of alternative monotherapy versus adjunctive therapy in partial epi...